バセドウ病に合併する甲状腺眼症、新規治療で眼の奥はどう変わるのか―MRIで筋肉と脂肪の変化を読み解く―

ad

2026-08-27 京都大学

京都大学大学院医学研究科の研究グループは、甲状腺眼症に対する新規治療薬テプロツムマブの効果をMRIで解析し、ステロイドパルス療法を中心とする従来治療と比較した。テプロツムマブでは、眼球を動かす外眼筋と眼窩脂肪の双方が縮小したのに対し、従来治療では外眼筋は縮小したものの眼窩脂肪が増加した。この違いが、従来治療で眼球突出の改善が限定的となる一因である可能性が示された。また、MRIで炎症が確認された外眼筋ほど治療後の縮小が大きく、複数の外眼筋に炎症がある患者では、テプロツムマブによる眼球突出の改善効果がより大きかった。MRIによる組織変化の解析は、治療効果の予測や患者ごとの治療選択に役立つ可能性がある。

バセドウ病に合併する甲状腺眼症、新規治療で眼の奥はどう変わるのか―MRIで筋肉と脂肪の変化を読み解く―
本研究の概要
京都大学医学部附属病院で行った観察研究。テプロツムマブの治療効果をMRIで詳細に解析し、ステロイドパルス療法を中心とした従来治療と比較しました。(作成者:山内一郎)

<関連情報>

⽇本⼈甲状腺眼症患者に対するテプロツムマブの効果:MRI を⽤いた静注グルココルチコイド療法との⽐較 Teprotumumab Effects on Thyroid Eye Disease in a Japanese MRI Study: Comparison with Intravenous Glucocorticoid Therapy

Ichiro Yamauchi,Daisuke Taura,Yohei Ueda,Taku Sugawa,Manabu Miyata,Akinari Yamamoto,Kenji Suda,Eri Nakano,Yo Kishimoto,Koji Nishimura,…
The Journal of Clinical Endocrinology & Metabolism  Published:25 August 2026
DOI:https://doi.org/10.1210/clinem/dgag348

Abstract

Context
Teprotumumab (TEP) is an emerging treatment for thyroid eye disease (TED), but real-world evidence outside the United States remains limited, and detailed changes in orbital components have not been fully clarified.

Objective
To evaluate the effectiveness of TEP based on clinical manifestations and magnetic resonance imaging (MRI) findings, and compare it with that of intravenous glucocorticoid (IVGC) therapy.

Methods
The TEP cohort included all 18 patients who started TEP therapy at Kyoto University Hospital by July 31, 2025. A historical IVGC cohort included 20 patients selected to improve comparability with the TEP cohort.

Results
During 24 weeks of TEP therapy, proptosis measured using a Hertel exophthalmometer improved from 22 (20–22) to 19 (16–21) mm (p = 0.025), and clinical activity score decreased from 4 (3–5) to 1 (0–1) point (p < 0.001). Among 15 patients with diplopia, a reduction of at least 1 point in Gorman score was observed in 9 patients (60.0%). Thyroid-stimulating antibody titers decreased from 1,180% (349–4,710) to 282% (132–504) (p = 0.013). MRI-based comparisons with the IVGC cohort showed that TEP reduced both extraocular muscle and orbital fat areas, whereas IVGC reduced extraocular muscle area but conversely increased orbital fat area. Inflamed extraocular muscles identified on MRI were enlarged at baseline and showed marked shrinkage after both therapies.

Conclusion
TEP showed robust effectiveness in Japanese real-world patients with TED. MRI-based analyses revealed distinct effects of TEP and IVGC on orbital fat and identified inflamed extraocular muscles as treatment-responsive components.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました